Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: A Pilot Study Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo in the Treatment of Moderate-to-severe Hidradenitis Suppurativa (HS).
Brief Summary: The study is a randomized, proof of concept study.
30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.
Dosage of deucravacitinib will be given according to the investigational regimen as follows: 6 mg po bid for 16 weeks.
The study compromises a 4-week screening period, a 16-week study period, and a 4-week follow-up period.
The follow-up period consists of a follow-up phone call 4 weeks after the last study drug dose.